HGF/c-Met comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
Dihexa is not approved for human use in the United States or the European Union. It is commonly sold as a research chemical, a category that may not require the same regulatory review as medicines. Buyers should note that product labels may lack independent verification of identity or purity. The legal status can vary by country, and importation may be restricted. Reliable information about sourcing and quality is often scarce. Scientific publications typically use synthesized material from laboratories rather than commercial consumer products.
Dihexa is a synthetic peptide studied in laboratory research. It is often described as an angiotensin IV analog or a hepatocyte growth factor mimetic. The compound emerged from investigations into angiotensin IV and its effects on neural pathways. It is not an approved medication, and controlled human trials are lacking. In literature and online forums, it is discussed mainly as a research chemical. Its chemical name appears as N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) in some sources.
Development of dihexa has been linked to academic research on synaptogenesis, the formation of new synapses. Preclinical studies in rodents have examined its effects on learning and memory tasks. These studies are often cited in discussions about cognitive enhancement, but they do not establish safety or efficacy in humans. The compound's patent and commercial history is limited, and it is not widely available through pharmaceutical channels. Most information comes from animal models and in vitro experiments. Researchers continue to explore its basic biology rather than clinical applications.
The angiotensin IV connection places dihexa in a family of short peptides studied for effects on central nervous system signaling. Angiotensin IV itself is a metabolite of angiotensin II, and analogs have been explored in cardiovascular and neurological research. Dihexa differs from the natural peptide through structural modifications intended to alter stability and receptor interactions. Published descriptions sometimes call it a hepatocyte growth factor mimetic, although that label reflects proposed activity rather than a confirmed clinical mechanism.
Identity checks for dihexa usually rely on mass spectrometry and chromatographic purity analysis. A lyophilized powder is the common supplied form, and it may appear as a white to off-white solid. Aqueous solubility is limited, so laboratory work often uses an organic solvent such as dimethyl sulfoxide to prepare stock solutions. Because the peptide is not a standard pharmaceutical product, exact specifications can vary between suppliers. Certificates of analysis may accompany a batch, but they are not equivalent to regulatory approval.
| Property | Value | Notes |
|---|---|---|
| CAS Registry Number | 1401708-83-5 | Identifier used in chemical databases. |
| Common synonyms | P21; N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) | Names vary by supplier and publication. |
| Physical form | White to off-white powder | Lyophilized solid typical of peptides. |
| Solubility | Soluble in DMSO; limited in water | Aqueous preparation may need a co-solvent. |
| Storage | -20 °C, desiccated, protected from light | Reduce freeze-thaw cycles to maintain stability. |
Discussion of dihexa in online communities sometimes outpaces the scientific record. Anecdotal reports are difficult to verify and may not distinguish effects from placebo or expectation. The absence of approved human data means long-term risks remain unknown. Researchers continue to investigate related compounds and pathways. Open questions include whether animal findings translate to humans and which biological targets matter most. No consensus exists on these points. Current reviews emphasize the need for rigorous clinical research.
Most published work on dihexa consists of preclinical studies using cell cultures or rodents. Reports have described effects on synaptic connectivity and performance on cognitive tasks in some animal models. These findings are generally presented as preliminary and require independent replication. Study designs, doses, and outcome measures vary across experiments, which complicates direct comparison. No large controlled human trials have established efficacy or safety for any medical use. At present, the evidence base is limited.
Animal studies have examined dihexa in models of cognitive impairment, synaptic plasticity, and memory. Some reports describe improved performance on maze or avoidance tasks after administration. These findings are preclinical and often involve small samples, varied routes, and differing formulations. Results in rodents do not establish effects in humans. The absence of published randomized controlled trials in people is a major gap in the evidence base. Observational reports and user accounts do not substitute for controlled clinical data.
Discussion in the literature often separates direct receptor activation from downstream growth-factor modulation. Dihexa is not simply an angiotensin receptor blocker or a classic nootropic drug. Its proposed action may depend on endogenous HGF levels, which vary by tissue and physiological state. Questions remain about brain penetration, metabolic stability, and active metabolites. Reviews note that mechanistic claims should be treated as hypotheses until supported by independent studies. That distinction is important when interpreting promotional claims or early laboratory findings.
== Diagnosis == Diagnosing hyperandrogenism can be complex due to the wide variety and severity of signs and symptoms that may present. It is most often diagnosed by checking for signs of hirsutism according to a standardized method that scores the range of excess hair growth. Girls may show symptoms of hyperandrogenism early in life, but physicians become more concerned when the patient is in her late teens or older. Checking medical history and a physical examination of symptoms are used for an initial diagnosis. Patient history assessed includes age at thelarche, adrenarche, and menarche; patterns of menstruation; obesity; reproductive history; and the start and advancement of hyperandrogenism symptoms. Patterns of menstruation are examined since irregular patterns may accompany hyperandrogenism. Other conditions that may present alongside hirsutism that can contribute to diagnosis include androgenic alopecia and acne. If hyperandrogenism is severe, virilization may occur. Family history is also assessed for occurrences of hyperandrogenism symptoms or obesity in other family members. Laboratory tests can measure FSH, luteininzing hormone, DHEAS, prolactin, 17α-hydroxyprogesterone, and total and free testosterone in the blood. Abnormally high levels of any of these hormones help in diagnosing hyperandrogenism.
Now EC 1.14.14.46, pimeloyl-[acyl-carrier protein] synthase EC 1.14.15.13: pulcherriminic acid synthase EC 1.14.15.14: methyl-branched lipid ω-hydroxylase EC 1.14.15.15: cholestanetriol 26-monooxygenase EC 1.14.15.16: vitamin D3 24-hydroxylase EC 1.14.15.17: pheophorbide a oxygenase EC 1.14.15.18: calcidiol 1-monooxygenase EC 1.14.15.19: C-19 steroid 1α-hydroxylase EC 1.14.15.20: heme oxygenase (biliverdin-producing, ferredoxin) EC 1.14.15.21: zeaxanthin epoxidase EC 1.14.15.22: vitamin D 1,25-hydroxylase EC 1.14.15.23: chloroacetanilide N-alkylformylase EC 1.14.15.24: β-carotene 3-hydroxylase EC 1.14.15.25: p-cymene methyl-monooxygenase EC 1.14.15.26: toluene methyl-monooxygenase EC 1.14.15.27: β-dihydromenaquinone-9 ω-hydroxylase EC 1.14.15.28: cholest-4-en-3-one 26-monooxygenase [(25R)-3-oxocholest-4-en-26-oate forming] EC 1.14.15.29: cholest-4-en-3-one 26-monooxygenase [(25S)-3-oxocholest-4-en-26-oate forming] EC 1.14.15.30: 3-ketosteroid 9α-monooxygenase EC 1.14.15.31: 2-hydroxy-5-methyl-1-naphthoate 7-hydroxylase EC 1.14.15.32: pentalenene oxygenase EC 1.14.15.33: pikromycin synthase EC 1.14.15.34: 20-oxo-5-O-mycaminosyltylactone 23-monooxygenase EC 1.14.15.35: 6-deoxyerythronolide B hydroxylase EC 1.14.15.36: sterol 14α-demethylase (ferredoxin) EC 1.14.15.37: luteothin monooxygenase EC 1.14.15.38: N,N-dimethyl phenylurea N-demethylase EC 1.14.15.39: epi-isozizaene 5-monooxygenase
=== Cementum and Periodontal Ligament === Surrounding the apical foramen is apical cementum, often cellular cementum embedded with cementocytes. Sharpey’s fibres from the periodontal ligament insert into this cementum, anchoring the tooth to alveolar bone.
Chevreul was born in the town of Angers, France, where his father was a physician. Chevreul's birth certificate, kept in the registry book of Angers, bears the signature of his father, grandfather, and a great-uncle, all of whom were surgeons. At around the age of seventeen, Chevreul went to Paris and entered L. N. Vauquelin's chemical laboratory, afterwards becoming his assistant at the Muséum national d'histoire naturelle (National Museum of Natural History) in the Jardin des Plantes. In 1813, Chevreul was appointed professor of chemistry at the Lycée Charlemagne, and subsequently undertook the directorship of the Gobelins tapestry works, where he carried out his research on colour contrasts. (In 1839, he published the results of his research under the title De la loi du contraste simultané des couleurs; It was translated into English and published in 1854 under the title The Principles of Harmony and Contrast of Colors. A new translation titled On the Law of Simultaneous Contrast of Colors, with commentary, additional chapters, and colour graphics by Dan Margulis, appeared in 2020.) In 1826, Chevreul became a member of the Academy of Sciences, and in the same year was elected a foreign member of the Royal Society of London, whose Copley Medal he was awarded in 1857. In 1829, he was elected a foreign member of the Royal Swedish Academy of Sciences and a Foreign Honorary Member of the American Academy of Arts and Sciences in 1868.
Sources: en.wikipedia.org
Sulfur–sulfur bonds are a structural component used to stiffen rubber, similar to the disulfide bridges that rigidify proteins (see biological below). In the most common type of industrial "curing" or hardening and strengthening of natural rubber, elemental sulfur is heated with the rubber to the point that chemical reactions form disulfide bridges between isoprene units of the polymer. This process, patented in 1843, made rubber a major industrial product, especially in automobile tires. Because of the heat and sulfur, the process was named vulcanization, after the Roman god of the forge and volcanism.
The reason why this trinucleotide (rather than the complementary tetramer) catalyzes this reaction may be because the UUU-AAA pairing is the weakest and most flexible trinucleotide among the 64 conformations, which provides the binding site for Mn2+. Phosphoryl transfer can also be catalyzed without metal ions. For example, pancreatic ribonuclease A and hepatitis delta virus (HDV) ribozymes can catalyze the cleavage of RNA backbone through acid-base catalysis without metal ions. Hairpin ribozyme can also catalyze the self-cleavage of RNA without metal ions, but the mechanism for this is still unclear. Ribozyme can also catalyze the formation of peptide bond between adjacent amino acids by lowering the activation entropy.
Sanders voted against the resolutions authorizing the use of force against Iraq in 1991 and 2002, and he opposed the 2003 invasion of Iraq. He voted for the 2001 Authorization for Use of Military Force Against Terrorists that has been cited as the legal justification for controversial military actions since the September 11 attacks. He especially opposed the Bush administration's decision to start a war unilaterally.
=== Other uses === Ammonium sulfate is a precursor to other ammonium salts, especially ammonium persulfate ((NH4)2S2O8. Ammonium sulfate is listed as an ingredient for many vaccines by the Centers for Disease Control. Ammonium sulfate has also been used in flame retardant compositions acting much like diammonium phosphate. As a flame retardant, it increases the combustion temperature of the material, decreases maximum weight loss rates, and causes an increase in the production of residue or char.
== External websites == Polypropylene Glycol (PPG) | Monument Chemical POLYPROPYLENE GLYCOL | CAMEO Chemicals | NOAA Poly(propylene glycol) (polymerdatabase.com) Polypropylene Glycol Safety Data Sheet
Sources: en.wikipedia.org
== Mechanism of action == Delta atracotoxin is responsible for the potentially lethal envenomation syndrome seen following funnel-web spider envenomation. d-Atracotoxins induce spontaneous, repetitive firing and prolongation of action potentials resulting in continuous acetylcholine neurotransmitter release from somatic and autonomic nerve endings. This will lead to slower voltage-gated sodium channel inactivation and a hyperpolarizing shift in the voltage-dependence of activation. This action is due to voltage-dependent binding to neurotoxin receptor site-3 in a similar, but not identical, fashion to scorpion a-toxins and sea anemone toxins. In the sea anemone and scorpion toxins, combinations of charged (especially cationic) and hydrophobic side-chains are important for binding to their receptor site (site 3) on the sodium channel. The same applies to delta atracotoxin and versutoxin (a close homologue of delta atracotoxin). Delta atracotoxin presents three distinct charged patches on its surface, as well as a non-polar region centered on the 22-28 loop. Both of these structural features may play a role in its binding to the voltage-gated sodium channel, but further studies are necessary in defining which residues are important for interaction with the sodium channel so that a plausible model can be constructed of its binding site.
{\displaystyle {\begin{aligned}z:\ &\rho \left({\partial _{t}u_{z}}+u_{x}{\partial _{x}u_{z}}+u_{y}{\partial _{y}u_{z}}+u_{z}{\partial _{z}u_{z}}\right)\\&\quad =-{\partial _{z}p}+\mu \left({\partial _{x}^{2}u_{z}}+{\partial _{y}^{2}u_{z}}+{\partial _{z}^{2}u_{z}}\right)+{\frac {1}{3}}\mu \ \partial _{z}\left({\partial _{x}u_{x}}+{\partial _{y}u_{y}}+{\partial _{z}u_{z}}\right)+\rho g_{z}.\end{aligned}}}
==== Hungary ==== In 1994, 265 mummified bodies were found in the crypt of a Dominican church in Vác, Hungary from the 1729–1838 period. The discovery proved to be scientifically important, and by 2006 an exhibition was established in the Museum of Natural History in Budapest. Unique to the Hungarian mummies are their elaborately decorated coffins, with no two being exactly alike.
The longest-lived non-ground state nuclear isomer is the nuclide tantalum-180m (180m73Ta), which has a half-life in excess of 1017 years. This nuclide occurs primordially, and has never been observed to decay to the ground state. (In contrast, the ground state nuclide tantalum-180 does not occur primordially, since it decays with a half-life of only 8 hours to 18072Hf (86%) or 18074W (14%).) There are 251 nuclides in nature that have never been observed to decay. They occur among the 80 different elements that have one or more stable isotopes. See stable nuclide and primordial nuclide. Unstable nuclides are radioactive and are called radionuclides. Their decay products ('daughter' products) are called radiogenic nuclides.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide investigated in preclinical research. It is often classified as an angiotensin IV analog or an HGF mimetic. It is not an approved medicine.
No. Regulatory agencies have not approved dihexa for human use. It is sold as a research chemical in some markets, and human safety and efficacy data are lacking.
Laboratory studies have examined its effects on synapse formation and cognitive tasks in animals. These are early-stage findings. They do not prove benefits or safety in people.
Dihexa is a synthetic peptide analog related to angiotensin IV. It is studied in preclinical research for effects on neural signaling and synapse formation. It is not an approved medicine.